logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Rigel Pharmaceuticals, Incorporated


USPTO Granted Patents = 488



Trademarks = 13

Forward Citations = 5,605

Loading Chart...
Loading Chart...

194 inventors (with patents filed for the assignee):

goldMedal Rajinder Paul Singh (292 out of 369 patents)

silverMedal Somasekhar Bhamidipati (138 out of 140 patents)

bronzeMedal Hui Li (131 out of 142 patents)

4.  Ankush Argade (96 out of 97 patents)

5.  Vanessa Taylor (88 out of 89 patents)

6.  Sacha Holland (88 out of 89 patents)

7.  Jeffrey Clough (85 out of 86 patents)

8.  Donald G Payan (85 out of 89 patents)

9.  Esteban Masuda (83 out of 84 patents)

10.  Jiaxin Yu (61 out of 67 patents)

11.  Holger Keim (60 out of 62 patents)

12.  Catherine Sylvain (55 out of 65 patents)

13.  Yan Chen (53 out of 79 patents)

14.  Dane A Goff (53 out of 60 patents)

15.  Kin Tso (52 out of 55 patents)


Core Competencies:
IRAK Inhibitors
RIP1 Kinase Inhibitors
Tyrosine Kinase Inhibitors
TGF-β Inhibitors
Pyrazole Compounds
Heterocyclic Compounds
Nrf2 Activating Compounds
Fumarate Analogs
Prodrugs
Autoimmune Disease Treatments
AMPK Activators
Benzazole Compounds

488 patents:

1. 12459941 - Tricyclic IRAK inhibitors (2025-11-04),
2. 12448366 - Solid forms of pralsetinib (2025-10-21),
3. 12441723 - Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations (2025-10-14),
4. 12384775 - Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors (2025-08-12),
5. 12357623 - Method for treating a disease or condition using a pyrazole compound or formulation thereof (2025-07-15),
6. 12331036 - Heterocyclic RIP1 kinase inhibitors (2025-06-17),
7. 12297202 - RIP1K inhibitors (2025-05-13),
8. 12263180 - Method for treatment of COVID-19-associated conditions (2025-04-01),
9. 12227508 - TGF-β inhibitors (2025-02-18),
10. 12156880 - Heterocyclic RIP1 kinase inhibitors (2024-12-03),
11. 12116354 - RIP1 inhibitory compounds and methods for making and using the same (2024-10-15),
12. 12043629 - RIP1K inhibitors (2024-07-23),
13. 12043620 - Benzazole compounds and methods for making and using the compounds (2024-07-23),
14. 11993594 - IRAK inhibitors and method for making and using (2024-05-28),
15. 11963958 - RET inhibitor for use in treating cancer having a RET alteration (2024-04-23),
Rigel Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. With a strong pipeline of potential therapies, Rigel aims to improve patient outcomes and quality of life.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
488 Patents

#3 in South San Francisco, CA

#218 in California

#955 in US

#1,917 in the World

...
South San Francisco, CA, United States of America

Rigel Pharmaceuticals, Incorporated

Forward Citations = 5,605

194 inventors:

goldMedal Rajinder Paul Singh (292 out of 369 patents)

silverMedal Somasekhar Bhamidipati (138 out of 140 patents)

bronzeMedal Hui Li (131 out of 142 patents)

4.  Ankush Argade (96 out of 97 patents)

5.  Vanessa Taylor (88 out of 89 patents)

Please report any incorrect information to support@idiyas.com
Loading…